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Abstract
Background/Aim: N-6 fatty acids are considered to pro-
mote diseases prevalent in industrialized countries and
characterized by an increased eicosanoid biosynthesis
from arachidonic acid (AA). We investigated the impact
of the linoleic acid (LA) intake on AA levels in humans.
Methods: Six healthy female volunteers (age range 23–
34 years) were given liquid formula diets (LFD) devoid of
AA for 6 weeks, providing a constant intake of zero ener-
gy% (LFD 0: protein 15%, carbohydrates 85%) or 20 ener-
gy% (LFD 20: protein 15%, carbohydrates 55%, fat 30%)
LA, for 3 weeks each. Fatty acids of plasma cholesteryl
esters and platelet lipids were determined each week,
and the prostaglandin biosynthesis was measured in 24-
hour urine samples. Results: LFD 0 increased (+31% of
initial value) and LFD 20 lowered (–30% of initial value)
the percentage of AA in plasma cholesteryl esters and
platelet lipids. Moreover, absence of dietary AA lowered
the percentages of AA in plasma (–31% week 0 vs. week
6) and platelet (–11%) lipids, indicating a low transforma-
tion of LA. LFD 0 reduced urinary metabolite levels of
prostaglandins D, E, and F in 24-hour urine samples
(–48%, p ! 0.001) within 24 h, but did not significantly
affect platelet aggregation (–10%) and thromboxane for-
mation (–25%). LFD 20 significantly lowered platelet ag-
gregation (–25%) and thromboxane formation (–43%).
The prostaglandin metabolite levels increased during
the first 10 days, declined thereafter, and were lower
than the preexperimental values at the end of the 3-week
period. Conclusions: The results show that dietary LA
does not increase the AA levels in plasma or platelet lip-
ids and does not persistently contribute to prostaglandin
biosynthesis which is increased by AA intake with West-
ern diets.
Copyright © 2003 S. Karger AG, Basel
Introduction
Linoleic acid (LA) is the precursor of arachidonic acid
(AA) in animals and in humans. The availability of AA is
positively correlated with the biosynthesis of eicosanoids
[1], especially thromboxane, which is elevated in athero-
sclerosis [2] and breast cancer [3]. Western diets are char-
acterized by a prevalence of n-6 fatty acids, both LA and
32 Ann Nutr Metab 2003;47:31–36 Adam/Wolfram/Zöllner
Table 1. Composition of conventional diet






Fat 35 85.6 30 77.3 0 0
Carbohydrates 50 268.2 55 295 85 456.1
Protein 15 80.7 15 80.7 15 80.7
LA 7.6 16.5 20 43.5 0 0
AA 0.3 0.63 0 0 0 0
KCl 4 3 3
NaCl 8 5 5
Cholesterol 0.6 0.6 0.6
AA. Excessive intake of n-6 fatty acids with Western diets
is incriminated as an important risk factor for diseases
with an increasing prevalence in industrialized countries,
like atherosclerosis, allergies, and immunological or cer-
tain neoplastic diseases [4]. To investigate the impact of
LA on the AA prevalence, we studied healthy female vol-
unteers being given liquid formula diets for 6 weeks, pro-
viding a defined intake of LA, but containing no AA.
Materials and Methods
Subjects
Six females (age range 23–34 years) were selected for the experi-
ment on the basis of the following criteria: their body weight was
within a body mass index of 20–24 kg/m2, they were free from known
metabolic abnormalities, and routine laboratory findings and clinical
examination were unremarkable. All were medical students and con-
tinued their normal life and physical activities throughout the experi-
ment. They came to the metabolic ward of the clinic every morning,
and body weight and energy intake were determined and clinical
evaluations performed. Most of the day they spent in the clinic, eat-
ing their formula diets under supervision.
Liquid Formula Diets
The compositions of the liquid formula diets (LFDs) and of the
conventional diet are shown in table 1. For each volunteer, the neces-
sary caloric intake was calculated to maintain the body weight. The
LFD 20 provided 20 energy% LA (43.5 g/2,200 kcal) included in the
total amount of 30 energy% of fat (appropriate mixtures of safflower
oil and olive oil). The protein intake with both LFDs containing 92%
whey protein was 15 energy% (Hyperprotidine; Laboratoires Guigoz,
Marne-la-Vallée, France). With the LFD 20, carbohydrates (Malto-
dextrine; Maizena, Krefeld, Germany) containing 94% oligopolym-
ers of glucose provided 55% and with the LFD 0 (containing no fat)
85% of the total energy intake. To ensure a constant composition of
dietary fat, appropriate mixtures of safflower oil and olive oil were
prepared before the experiment, stored under nitrogen, and deep-
frozen (–20°C) in brown bottles until use. The fatty acid composi-
tion was checked before and every week during the experiment.
LFDs were prepared each day for every volunteer in amounts ensur-
ing an adequate caloric intake; 3 g KCl, 5 g NaCl, and 0.6 g cholester-
ol were added per 2,200 kcal LFD, 1 capsule of vitamins (Protovita;
Roche, Grenzach-Whylen, Germany) was given daily, and 100 mg of
FeCl2 was given every other day. Water intake was allowed ad libi-
tum.
Experimental Design
Eight days before the experiment, our volunteers started record-
ing their diet to calculate their usual caloric intake. Then the volun-
teers were randomized and allocated to LFD 0 or LFD 20. Three of
them (volunteers A, B, and C) were started on LFD 20, the remaining
3 (volunteers D, E, and F) on LFD 0, changing to the other LFD after
3 weeks. The experiments were approved by the ethical committee of
the institution, and written informed consent was given by the volun-
teers.
24-hour urine samples were collected 8 days before and during
the experimental period by each volunteer, the volumes of which
were immediately determined and the samples deep-frozen (–20 °C)
in appropriate amounts until analysis of prostaglandin (PG) and uric
acid levels. The LFDs were free from purines, and adherence to
LFDs was monitored by measuring the uric acid excretion. Fasting
venous blood samples were collected in EDTA-coated tubes every
2nd day (4 times) during the preexperimental period and every 7th
day during each experimental period. For platelet aggregation stud-
ies, venous blood samples were collected in trisodium citrate (final
concentration 12.9 mM ). At the same time points nonanticoagulated
blood samples (2 ! 1 ml) were taken for determinations of serum
thromboxane levels expressed as thromboxane B2 (TXB2).
Measurements
Cholesteryl esters (CE) were isolated by thin-layer chromatogra-
phy on precoated silica gel plates (Schleicher & Schuell, Dassel, Ger-
many) and identified by standards (Sigma, Freiburg, Germany) on
each plate as described elsewhere [5]. Total cholesterol and free cho-
lesterol concentrations were determined by a commercial test set
(Boehringer Mannheim, Germany), and cholesterol esters were cal-
culated as difference of these values. Platelets were isolated from
EDTA-plasma by fractional centrifugation, deep-frozen at –20oC,
and lipids were extracted as previously described [6]. Methyl esters
were prepared by transmethylation with 5% HCl in CH3OH [5], and
capillary gas-liquid chromatography was performed on a Fractovap
series 4160 apparatus equipped with a flame ionization detector and
a Spectra Physics SP 4100 computing integrator (Carlo Erba, Milan
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Italy). The capillary fused silica column was coated with M20
(Chrompack, Berlin, Germany). Most samples were run in duplicate,
questionable samples were reexamined on a Hewlett-Packard model
5971a gas-liquid chromatography-mass spectrometry system. The
known molar weight, the amount of CE, and the percentages of LA,
dihomo-Á-LA, and AA in CE allowed for calculating the quantities
(mg%) of these fatty acids.
Determinations of uric acid were done using a Technicon auto-
analyzer II system (Technicon Instruments, Tarrytown, N.Y., USA)
by a routine method (Boehringer Mannheim, Germany). The urinary
PG metabolites were determined by measuring tetranorprostanedio-
ic acid (TNPDA), the joint metabolite of PGD, PGE, and PGF, on
two packed columns with liquid phases of different polarity (M20
and SP2340; Chrompack), as previously described [7]. The serum
TXB2 concentration was measured in duplicate in 1 ml of nonanti-
coagulated blood samples which were allowed to clot in a tube at
37°C for 1 h. TXB2 was measured by a commercial radioimmunoas-
say (Code NEK-024; Du Pont de Nemours, Bad Homburg, Germa-
ny).
The platelet aggregation was measured with a Born-type aggre-
gometer (Fresenius, Oberursel, Germany). Following a 10-min incu-
bation period at 37°C in a shaking water bath, platelet aggregation to
collagen was performed in aliquots (0.5 ml) from each sample in trip-
licate, as previously described [6].
Statistics
Statistical analyses were performed using the nonparametric two-
way analysis of variance (Friedman test); statistical differences were
determined by using the Wilcoxon signed-rank test [8]. The resulting
two-by-two frequency table was evaluated descriptively by the chi-
square test (exact Fisher test) [8].
Results
All volunteers completed the study without noticeable
side effects. The adherence to the LFDs was good, as
assessed by determination of the uric acid excretion. No
difference between both LFDs was found for the uric acid
excretion which returned to the basal levels of 258 B 16
mg/dl in the study participants on purine-free LFDs. The
low amount of sodium in LFDs caused an average loss of
body water of 1.1 kg during the first 3 days on LFD. The
volunteers’ switching to the other LFD after the crossing-
over had no effect on the body weight which remained
constant within B 0.5 kg after the first 3 days during the
rest of the experimental period.
With the LFD 0, the LA decreased in CE of plasma
from 49 B 4.8% to 36.5 B 3.3% (fig. 1). With the LFD
20, an enrichment of LA was observed which already was
completed after the 2nd week on LFD 20 (fig. 1).
AA and DHGLA percentages in plasma cholesteryl
esters were inversely correlated to LA (table 2). With the
LFD 0, the AA concentration in CE increased from 11.3
B 2.3% to 15.2 B 2.1% of total fatty acids as compared
Fig. 1. Percentage of LA ()) and AA ($) in CE of plasma measured
after 1, 2, and 3 weeks in the volunteers on LFD 0 and LFD 20.
Table 2. Plasma concentrations (mg/100 ml) of LA, Á-linolenic acid,
and AA in plasma CE
LFD 0 LFD20
LA 16.2B1.4 30.0B3.1*
Á-Linolenic acid 2.1B0.1 1.1B0.1
AA 7.2B0.6 4.8B0.4*
* p ! 0.05 (Wilcoxon signed-rank test).
with the values measured in the volunteers on a conven-
tional diet (p ! 0.01). Most of the increase was reached
already after the 2nd week on the LFD 0 (fig. 1). The
increase of cholesteryl linoleate with the LFD 20 lowered
the AA concentration in CE from 10.3 B 2.9% to 8.1 B
1.2% after 3 weeks on this diet (p ! 0.01). We found a
distinct influence of the precedent diet on cholesteryl ara-
chidonate. In experimental subjects A, B, and C, coming
from a highLA intake with the LFD 20, the increase in the
AA concentration with the LFD 0 was less pronounced
(30% over preexperimental value than in subjects D, E,
and F, starting with the LFD 0 (51%; fig. 2). The LFD 20
reduced the AA concentration by 31% in subjects A, B,
and C and by 51% in subjects D, E, and F (p ! 0.01;
fig. 2).
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Fig. 2. AA levels measured in plasma CE of the volunteers A, B, and
C, starting on the LFD 20 (d) and thereafter put on the LFD 0 (o),
and volunteers D, E, and F, starting on the LFD 0 ([) and thereafter
put on the LFD 20 (P). The values are given as mean percentages of
the preexperimental value (conventional diet).
Table 3. LA and AA concentrations (mean B SD) in platelet phos-
pholipids of 6 healthy females measured before the experiment, with
the volunteers on a conventional diet and at the end of LFD 0 and




LFD 0 LFD 20
LA, % of total
fatty acids 5.8B1.2 4.5B0.6 8.3B1.1a,b
AA, % of total
fatty acids 41.4B1.4 37.1B1.1a 35.4B1.1a
a p ! 0.01 versus preexperimental value.
b p ! 0.01 versus LFD 0 (Wilcoxon signed-rank test).
Table 4. TXB2 and platelet aggregation measured in 6 healthy volun-
teers during LFD 0 and LFD 20 compared to the values measured
during conventional diet (0.3 g/day AA)
% reduction compared to
preexperimental value
LFD 0 LFD 20
TXB2 –25 –43*
Platelet aggregation –10 –25*
* p ! 0.01 versus the preexperimental value (Wilcoxon signed-
rank test).
At the end of the 6 weeks on LFD, the mean AA values
in CE were approximately 20% lower than the preexperi-
mental values, indicating a decrease of AA in CE during
LFDs devoid of AA.
Total cholesterol and CE decreased during LA intake
with the LFD 20. Consequently, the concentrations of LA
and DHGLA in plasma decreased more than their rela-
tive percentage values (table 2). In platelet lipids, the per-
centage of LA decreased by –22% during the LFD 0, and
at the end of the LFD 20, an increase of 43% was
observed. In contrast to the findings in CE, the AA con-
centration was lowered with both LFDs in platelet lipids
(table 3).
The eicosanoid biosynthesis, measured as TNPDA,
decreased within 24 h with the experimental subjects on
the LFD 0 (fig. 3). With the LFD 20 an increase of eicosa-
noids transformable to TNPDA was observed till the 10th
day, then the TNPDA levels gradually decreased, and we
found lower amounts in the 24-hour urine samples than
observed with the conventional diet. Platelet aggregation
and TXB2 formation were decreased during all LFD, and
the augmented LA intake with LFD 20 additionally low-
ered both parameters (table 4).
Discussion
Diets high in LA may have adverse effects, if they
result in augmented availability of AA, the precursor of
eicosanoids. Exaggerated eicosanoid formation promotes
platelet aggregation and mediates immunological, prolif-
erative, and allergic responses of cells [9]. Transformation
of LA to AA is an enzymatic process, dependent on the
activity of ‰-6-desaturase, an enzyme inhibited by all
polyunsaturated fatty acids, including LA [10, 11]. With
the LFD 20, we observed an impressive decrease in the
percentage of AA in CE of plasma which can be attributed
either to inhibition of desaturases or replacement of AA
on the binding sites by LA or displacement of AA in cell
lipids. In platelet lipids we found no significant differ-
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Fig. 3. Mean values (B SEM) of TNPDA, the joint metabolite of PGE, PGF, and PGD, measured in 24-hour urine
samples in the volunteers A–F on a Western diet (preexperimental) and on the LFD 20 (dark columns) or the LFD 0
(open columns).
ences in AA percentages with LFD 0 or LFD 20. So we
were unable to find a displacement of AA in cell lipids. In
cell cultures, LA competes poorly with AA for incorpora-
tion [12]. Inhibition of LA desaturation, seems relevant in
humans, as in our experiments the DHGLA and AA lev-
els were decreased with the LFD 20. The biosynthesis of
AA from LA is sluggish [11], but increases with fasting
[13] or diets devoid of polyunsaturated fatty acids [9].
This was confirmed by the increase of the AA concentra-
tions with the LFD 0 in our experiments.
The LFD 20 transiently increased the PGD, PGE, and
PGF levels transformable to TNPDA (fig. 3). It seems fea-
sible that excessive amounts of LA, as provided by the
LFD 20, result in a replacement of AA to maintain an
appropriate cell fluidity. This process may continue, until
normal cell fluidity is regained, thus leading to a tempo-
rarily increased release of AA and stimulated PG biosyn-
thesis [7]. This process is terminated after 2 weeks, when
we observed a reduction of TNPDA despite the continued
high LA intake. It cannot be excluded that formation of
isoprostanes additionally contributes to the temporarily
increased TNPDA formation [14].
With the LFD 0, the AA concentrations increased in
the CE of our volunteers. It is very unlikely that release of
AA from fat stores contributes appreciable to the increase
in AA levels, as both LFD 0 and LFD 20 provided the
same amount of energy, and our volunteers did not loose
weight during the LFD 0. Moreover, it is known that
release of AA from fat stores is very limited, as AA mostly
is stored in the sn-3 position of triglycerides which is not
accessible for lipases [9]. It is interesting that exclusion of
LA from the diet augments AA percentages in CE of plas-
ma, but lowers PG biosynthesis. AA has been supposed to
contribute essentially to cell membrane fluidity [15], and
eventually this compartment is not accessible for the
activity of phospholipase A2, relevant to release of AA and
subsequent PG biosynthesis [16]. Our findings would fit
excellently into the concept that desaturation of fatty
acids regulates cell fluidity and does not favor the AA cas-
cade for PG formation. This assumption is affirmed by
the findings in rats given a fat-free diet [17]. After 18
weeks on the diet, the overall degree of unsaturation in
phosphatidyl choline fatty acids was not decreased and
always higher in the outer than in the inner leaflets of liver
microsomal membranes.
LFD devoid of AA decreased the percentage of this fat-
ty acid during the 6-week experimental period, indicating
that endogenous AA formation was not sufficient to
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maintain the high levels of AA provoked by the intake of
AA with meat and other products of animal origin in our
volunteers during the preexperimental period on a West-
ern diet. This finding is consistent with results of other
experiments obtained with LFDs devoid of AA [7]. Also
with conventional diets high in LA, only minor changes in
AA percentages are observed [18]. Investigations per-
formed in vegetarians, living on a diet without animal
products, revealed that the AA percentages in blood, cells,
and tissues are lower than in omnivores [19]. These find-
ings underline the importance of dietary AA provided
with products of animal origin.
The importance of dietary AA is further strengthened
by the finding of inhibited platelet aggregation and re-
duced TXB2 formation with both LFDs (table 4). The dif-
ference in fatty acid composition of plasma lipids and
platelets is consistent with results reported in the litera-
ture and may indicate a special metabolic behavior of
platelets [20]. Despite unaltered percentages of AA, aug-
mentation of LA has been shown to diminish TXB2
release and platelet response to aggregating agents [21],
similar to the findings in our experiments.
In conclusion, we found that the transformation of LA
to AA in our volunteers was very low, leading to an
inverse relationship of dietary LA intake and percentages
of AA in CE during LFDs devoid of AA. The reduction of
AA by LA depends on a diet devoid of AA, e. g., a vegetar-
ian diet, as experiments with a conventional diet fail show
this effect [18]. In view of common diseases in Western
societies, such as atherosclerosis or immunologic or aller-
gic diseases, this points to the importance of dietary AA in
maintaining unwanted high levels of this precursor of
eicosanoids.
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